Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Dingjiang Liu"'
Characterization of Microbial Growth Potential in Antibody Drug IV Admixtures by Microbial Challenge
Autor:
Qingyan Hu, James Wu, Ka Po Chu, Yuan Cao, Douglas Kamen, Mary Kleppe, Yuan Cheng, Dingjiang Liu, Mohammed Shameem
Publikováno v:
Journal of Pharmaceutical Sciences.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6455b2ff113220ffc261d1b434fbd753
https://doi.org/10.1016/j.xphs.2023.05.011
https://doi.org/10.1016/j.xphs.2023.05.011
Autor:
Xiaobin Xu, Aming Zhang, Yingjie Xu, Yuan Cao, Stephen Cale, Matthew Franklin, Prasad Sarangapani, Peter M. Ihnat, Haibo Qiu, Dingjiang Liu, Erica A. Pyles, Mohammed Shameem, Ning Li
Publikováno v:
Journal of Pharmaceutical Sciences. 111:1335-1345
High concentration formulations of therapeutic monoclonal antibodies (mAbs) are highly desired for subcutaneous injection. However, high concentration formulations can exhibit unusual molecular behaviors, such as high viscosity or aggregation, that p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b5df5011bc0d9950e5e4b7d3f135ef7
https://doi.org/10.1016/j.xphs.2021.12.027
https://doi.org/10.1016/j.xphs.2021.12.027
Autor:
Dingjiang Liu, Mohammed Shameem
Publikováno v:
Therapeutic Delivery
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d709e978bfda89b7c7e8fc88c3e1c9ed
https://doi.org/10.4155/tde-2021-0079
https://doi.org/10.4155/tde-2021-0079
Autor:
Dongdong Wang, Jason K. Cheung, Christine Nowak, Yingda Xu, Ning Li, Wei Xu, Bruce Mason, Tony Rossomando, Dingjiang Liu, Diane D Dong, Alain Beck, Joanne Sun, Amit Katiyar, Tao Xiang, Hongcheng Liu, Smita Raghava
Publikováno v:
mAbs. 11:239-264
Increasing attention has been paid to developability assessment with the understanding that thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid delays during late-stage development. The concept of developability is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::403349622c416a603ec56c3e5223e638
https://doi.org/10.1080/19420862.2018.1553476
https://doi.org/10.1080/19420862.2018.1553476
Publikováno v:
Journal of pharmaceutical sciences. 110(10)
In recent years, monoclonal antibodies (mAb) have become one of the most important classes of therapeutic proteins. Among many of the quality attributes monitored and controlled throughout therapeutic antibody development, particulate matter is one o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::080e84026b6397ae8d55f535e46c92db
https://pubmed.ncbi.nlm.nih.gov/34139261
https://pubmed.ncbi.nlm.nih.gov/34139261
Autor:
Gitanjali Sharma, Chen Zhou, Saurabh Wadhwa, Ashwin C. Parenky, Kenneth S. Graham, Amardeep S. Bhalla, Dingjiang Liu, Hunter H. Chen, Mohammed Shameem
Publikováno v:
Ophthalmic Product Development ISBN: 9783030763664
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8e363b9163abc177f3d0c51cc3cefc1
https://doi.org/10.1007/978-3-030-76367-1_17
https://doi.org/10.1007/978-3-030-76367-1_17
Publikováno v:
International Journal of Pharmaceutics. 615:121464
Adeno-associated virus (AAV) has become an emerging tool for human gene therapies. Currently, AAV gene therapies are subjected to multiple freeze-thaw cycles during manufacturing, storage, transportation, and administration. While studies have shown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cf69abdd2d8295adccc9e9457d5aa8e
https://doi.org/10.1016/j.ijpharm.2022.121464
https://doi.org/10.1016/j.ijpharm.2022.121464
Publikováno v:
Development of Biopharmaceutical Drug-Device Products ISBN: 9783030314149
This book chapter covers practical consideration and strategies in developing high concentration formulations and drug products for commercial use. The discussions presented in this chapter are based on authors’ hands-on experience supplemented wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36c2ddfde4f74c48d4692cbb8812c3e0
https://doi.org/10.1007/978-3-030-31415-6_14
https://doi.org/10.1007/978-3-030-31415-6_14
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 193:113703
A co-formulated monoclonal antibody (mAb) product containing two or more antibodies offers several therapeutic advantages. However, quantitating the individual antibodies in a co-formulated product is challenging due to the similar biochemical and bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::697b8c518eff354a336beabd95fcf19c
https://doi.org/10.1016/j.jpba.2020.113703
https://doi.org/10.1016/j.jpba.2020.113703
Autor:
Peter M. Ihnat, Katherine Taylor, Chakravarthy Nachu Narasimhan, Dingjiang Liu, Valentyn Antochshuk, Jason E. Fernandez, Kapil Gupta, Daniel Dix, Eric Routhier, Elaine S.E. Stokes, Truong Nobel T, Sorina Morar-Mitrica, Fleming Michael, James K. Kranz, Diluzio Willow, Christine Wurth, George Crotts, Bing He, Monica L. Adams, Tanvir Tabish
Publikováno v:
Journal of pharmaceutical sciences. 107(2)
The Biophorum Development Group (BPDG) is an industry-wide consortium enabling networking and sharing of best practices for the development of biopharmaceuticals. To gain a better understanding of current industry approaches for establishing biopharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::061474570a3b0f2fc78623421fb44679
https://pubmed.ncbi.nlm.nih.gov/29074375
https://pubmed.ncbi.nlm.nih.gov/29074375